Details
ECLI
Source
Decision form
Issue date
Last update
File mark
Court
Jurisdiction
Judge
Žiadne známe citácie.
62025TO0637(01)_en.html
HTML · 30.67 KB
No categories available
62025TO0637(01)
ORDER OF THE GENERAL COURT (Ninth Chamber)
12 October 2026 (*)
In Case T‑637/25,
Merck Europe BV, established in Amsterdam (Netherlands), represented by P. Bogaert and Z. Bertrand, lawyers,
applicant,
v
European Commission, represented by E. Mathieu and A. Spina, acting as Agents,
defendant,
THE GENERAL COURT (Ninth Chamber),
composed of S. Kingston, President, A. Marcoulli and J. Hettne (Rapporteur), Judges,
Registrar: T. Henze, Acting Registrar,
having regard to the order of 12 December 2025, Merck Europe v Commission (T‑637/25 R, not published, EU:T:2025:1107),
having regard to the written part of the procedure,
makes the following
Order
1 By its application under Article 263 TFEU, the applicant, Merck Europe BV, seeks the annulment of the letter sent by the European Commission to the Bundesinstitut für Arzneimittel und Medizinprodukte (Federal Institute for Drugs and Medical Devices, Germany; ‘the BfArM’) on 11 July 2025 headed ‘Request for administrative assistance concerning the scope and extent of the marketing authorisation for MAVENCLAD – cladribine’ (‘the contested measure’).
Background to the dispute
2 The applicant is a pharmaceutical company.
3 On 22 August 2017, the Commission adopted Implementing Decision C(2017) 5888 (final) granting marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council for ‘MAVENCLAD – cladribine’, a medicinal product for human use. By that decision, the Commission granted Merck Serono Europe Limited a marketing authorisation for the medicinal product ‘MAVENCLAD – cladribine’ (‘the MA’).
4 The medicinal product ‘MAVENCLAD – cladribine’ (‘Mavenclad’) is indicated for the treatment of adults with highly active relapsing multiple sclerosis (‘MS’), as defined by clinical or imaging features.
5 MS is a chronic, inflammatory, demyelinating disease of the central nervous system that can result in neurological impairment and severe disability.
6 Article 1 of Implementing Decision C(2017) 5888 (final) is worded as follows:
‘The marketing authorisation provided for in Article 3 of Regulation (EC) No 726/2004 is granted for the medicinal product “MAVENCLAD – cladribine”, the characteristics of which are summarised in Annex I to this Decision. …’
7 Section 4.2 of the summary of product characteristics set out in Annex I to the MA provides for the posology and method of administration of Mavenclad:
‘Treatment must be initiated and supervised by a physician experienced in the treatment of MS.
Posology
The recommended cumulative dose is 3.5 mg/kg body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year. …
Following completion of the 2 treatment courses, no further cladribine treatment is required in years 3 and 4 (see section 5.1). Re-initiation of therapy after year 4 has not been studied
…’
8 By Implementing Decision C(2018) 4512 (final) of 9 July 2018 transferring and amending the marketing authorisation granted by Decision C(2017) 5888 (final) for ‘MAVENCLAD – cladribine’, a medicinal product for human use, the Commission transferred the MA to the applicant.
9 On 25 April 2022, the Commission adopted Implementing Decision C(2022) 2797 (final) on the renewal of the marketing authorisation for the medicinal product for human use ‘MAVENCLAD – cladribine’, granted by Decision C(2017) 5888 (final).
10 On 22 November 2023, the applicant submitted an application for variation of the terms of the MA, in which it requested, inter alia, the addition of the following wording in section 4.2 of the summary of product characteristics: ‘following completion of the first 4-year treatment period, treatment may be continued in year 5 or later at the discretion of the treating physician’.
11 On 1 February 2024, in the course of the assessment procedure for the requested amendment, the Rapporteur of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) raised an objection to the proposed addition to section 4.2 of the summary of product characteristics, stating that ‘given the existing uncertainties about the long-term efficacy and safety associated with additional treatment cycles of Mavenclad beyond year 4 that are to be defined as off-label use, the proposed sentence should not be included’, and adding that if the applicant were to pursue its application to amend that section, it should provide data on the long-term efficacy and safety of additional treatment cycles beyond year four.
12 Given that preliminary scientific assessment by the CHMP Rapporteur, the applicant withdrew its application for the amendment of section 4.2 of the summary of product characteristics.
13 On 17 March 2025, in the course of a procedure conducted under Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC (OJ 2014 L 158, p. 1), the BfArM asked the Commission to provide it with administrative assistance concerning the question whether the continuation of treatment with the medicinal product Mavenclad by repeated administration from year five onwards was covered by the MA.
14 On 11 July 2025, after consulting EMA, the Commission sent to the BfArM the contested measure, by which it stated that the use of Mavenclad beyond year four after the initial treatment was not covered by the terms of the MA, in particular the summary of product characteristics.
Forms of order sought
15 The applicant claims that the Court should:
– annul the contested measure;
– order the Commission to pay the costs.
16 The Commission contends that the Court should:
– dismiss the action as inadmissible;
– order the applicant to pay the costs.
17 In its observations on the plea of inadmissibility, the applicant contends that that plea should be rejected.
Law
18 Under Article 130(1) of the Rules of Procedure of the General Court, if the defendant makes an application to that effect, the Court may rule on the plea of inadmissibility without going to the substance of the case. Pursuant to Article 130(6) of those rules, the Court may decide to open the oral part of the procedure in respect of that application.
19 In the present case, since the Commission has applied for a decision on the inadmissibility of the action, the Court, considering that it has sufficient information available to it from the documents in the file, has decided to rule on that application without opening the oral part of the procedure.
20 In support of its plea of inadmissibility, the Commission argues, first, that the contested measure does not constitute a challengeable act and, second, that the applicant has neither an interest in bringing proceedings nor standing to bring proceedings.
21 As regards whether the contested measure is open to challenge, the Commission submits that, according to settled case-law, only acts producing binding legal effects which bring about a distinct change in an applicant’s legal position may form the subject matter of an action for annulment. Whether an act is open to challenge must be assessed in the light of the content of that act, its context and the powers and intention of the institution which adopted it.
22 According to the Commission, the contested measure, addressed to the BfArM in response to a request for administrative assistance, is merely a confirmation of the information already contained in the MA and in the summary of product characteristics. That measure does not amend the MA or create new rights or obligations for the applicant. It is therefore purely declaratory in nature.
23 In its view, the alleged restriction of the MA, invoked by the applicant, is simply the result of the fact that the summary of product characteristics states that the resumption of treatment after year four had not been studied. The contested measure therefore merely clarified the scope of the MA, without producing independent legal effects.
24 Indeed, the applicant’s legal situation in relation to Mavenclad is defined exclusively by EU pharmaceutical legislation and by the MA. The latter can be amended only once the procedures provided for inter alia by Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human and establishing a European Medicines Agency (OJ 2004 L 136, p. 1) have been completed.
25 According to the Commission, in the present case, the contested measure does not form part of a procedure for the variation of the MA. The contested measure, which merely responds to a request for administrative assistance, cannot therefore amend the MA.
26 As regards the context, the contested measure forms part of a national procedure relating to the authorisation of a clinical trial, which only the BfArM can grant. Thus, in its view, the fact that the Commission replied to the BfArM’s request for administrative assistance, in order to clarify the scope of the MA, does not mean that the contested measure was intended to have binding legal effect or, in particular, to vary the terms of the MA.
27 Lastly, the contested measure does not contain any new element nor is it based on a new scientific assessment; it merely recalls the conditions of use of Mavenclad laid down in the summary of product characteristics. The case-law relied on by the applicant concerning acts producing binding legal effects is therefore irrelevant.
28 The applicant submits that, by taking the view that the use of Mavenclad after the fourth year following the start of the treatment was not covered by the terms of the MA, the Commission introduced a new restriction which did not appear in the terms of the MA. That restriction alters the legal position of the applicant in so far as it is henceforth prevented from marketing and promoting Mavenclad for additional treatment cycles.
29 According to the applicant, the Commission’s main argument for considering that the resumption of treatment after year four was not covered by the terms of the MA is based on a principle that the use of a medicinal product within the scope of an authorised indication should be regarded as falling outside the scope of a marketing authorisation if that use has not been specifically studied. The Commission has not, however, adduced any evidence to demonstrate the existence of such a principle in EU law or in regulatory practice.
30 Regulatory practice shows, on the contrary, that the absence of specific studies does not prevent an unstudied use being regarded as consistent with that product’s marketing authorisation. The applicant cites in that regard several examples illustrating that practice.
31 In addition, in the view of the applicant, in accordance with the regulatory practice regarding the drafting of the summary of product characteristics, that summary defines the scope of the marketing authorisation and the limits, which must be explicitly mentioned, on the use of a medicinal product in the context of its authorised indication. Such limits could include, inter alia, a restriction on the number of treatment cycles or to certain categories of patients.
32 In that regard, the applicant relies on examples of medicinal products for which such limits have been expressly included in the summary of product characteristics where the regulatory authority intended to limit the scope of the authorised indication.
33 It argues that, in the present case, neither sections 4.1, 4.2 and 4.3 of the summary of product characteristics for Mavenclad nor any other provision therein set out comparable limitations regarding the resumption of treatment after year four. The mere statement that the use of Mavenclad after year four has not been studied cannot therefore be interpreted as excluding such use from the scope of the MA, since no express limitation is provided for therein.
34 In those circumstances, according to the applicant, the contested measure introduces a new restriction which does not follow from the terms of the MA and produces independent legal effects in that it restricts, for the first time, the conditions of use of Mavenclad resulting from the MA. That measure therefore constitutes a new element, which precludes it from being classified as an act confirming a previous decision.
35 The applicant also disputes the Commission’s arguments based, first, on the fact that the contested measure does not explicitly identify the legal basis in Regulation No 726/2004 on which it was adopted, second, on the fact that the procedure for variation of the MA which the applicant initiated in 2023 before halting it shows that the applicant was aware that Mavenclad was authorised only for treatment for a period of four years and, third, on the context in which that act was adopted, maintaining that none of those arguments can call into question the legally binding nature of the position adopted by the Commission in the contested measure. The applicant points out, in particular, that the contested measure was adopted in response to a request from the BfArM seeking the adoption of a legally binding position by the Commission, producing effects vis-à-vis third parties.
36 As a preliminary point, the Court notes that, according to settled case-law, the action for annulment provided for in Article 263 TFEU is available in the case of all measures adopted by the institutions, whatever their form, which are intended to have binding legal effects (see judgment of 12 July 2022, Nord Stream 2 v Parliament and Council, C‑348/20 P, EU:C:2022:548, paragraph 62 and the case-law cited).
37 In order to ascertain whether an act produces such effects and may, accordingly, form the subject matter of such an action, it is necessary to examine the substance of that act and to assess those effects in the light of objective criteria, such as the content of that act, taking into account, as appropriate, the context in which it was adopted and the powers of the institution, body, office or agency which adopted the act (see judgment of 18 June 2024, Commission v SRB, C‑551/22 P, EU:C:2024:520, paragraph 65 and the case-law cited).
38 Whether an act is open to challenge must therefore be assessed objectively, on the basis of its substance, and not by reference to the applicant (judgment of 10 February 2026, WhatsApp Ireland v European Data Protection Board, C‑97/23 P, EU:C:2026:81, paragraph 68).
39 Accordingly, it is not only preparatory acts which fall outside the scope of the judicial review provided for in Article 263 TFEU but any act not producing legal effects that are binding on and capable of affecting the interests of the individual, such as confirmatory measures and purely implementing measures, mere recommendations and opinions and, in principle, internal instructions (see order of 14 May 2012, Sepracor Pharmaceuticals (Ireland) v Commission, C‑477/11 P, not published, EU:C:2012:292, paragraph 52 and the case-law cited).
40 It is therefore necessary to determine, in the light of the case-law referred to in paragraphs 36 to 39 above, whether, in the present case, the contested measure produces binding legal effects.
41 In the first place, as regards the content of the contested measure, it should be noted, first, that, in that measure, the Commission responds to a request for administrative assistance concerning the scope of the MA, sent by the BfArM to the Commission during a procedure conducted at national level under Regulation No 536/2014. Moreover, the heading of the contested measure explicitly states that it relates to a request for administrative assistance.
42 Second, in the contested measure, the Commission stated that the BfArM had asked it to confirm whether the continuation of treatment with the medicinal product Mavenclad by repeated administration from year five onwards was covered by the MA.
43 Third, in the contested measure, the Commission stated that it had consulted EMA on account of the technical nature of the question raised by the BfArM and EMA’s role in the initial and ongoing scientific assessment of the MA, and relied on the technical reply provided by EMA in order to respond to the request for administrative assistance submitted by the BfArM.
44 Fourth, in the contested measure, the Commission stated that the use of Mavenclad beyond year four after the initial treatment was not covered by the terms of the MA, in particular the summary of product characteristics, and attached, inter alia, that summary and EMA’s technical reply to its response.
45 It is apparent from the wording of the contested measure that, by that measure, the Commission merely provided the BfArM with information concerning the scope of the MA in the light of its content. Furthermore, that measure contains no element that could be understood as imposing obligations, conferring rights or altering the scope of the MA.
46 Accordingly, the Commission confined itself to responding to the request for administrative assistance submitted by the BfArM, without altering the scope of the MA or suspending or withdrawing it.
47 Furthermore, it is not apparent from either the wording or the content of the contested measure that the Commission intended to initiate a procedure capable of leading to the adoption of an act producing binding legal effects.
48 In the second place, as regards the context of the contested measure, the following should be noted.
49 First, as is apparent from section 4.2 of the summary of product characteristics, the MA provides for a treatment regimen limited to two treatment cycles over two years and specifies (i) that no further treatment is required during years three and four and (ii) that resumption of treatment after year four has not been studied.
50 Second, as noted in paragraphs 10 to 12 above, in 2023 the applicant submitted an application for variation of the terms of the MA in order to allow treatment to continue beyond year four. That application was withdrawn after the CHMP Rapporteur, as part of his scientific assessment, raised an objection to that application, taking the view that it related to off-label use of the medicinal product.
51 Third, the BfArM informed the Commission that its request for administrative assistance was made in a context in which it had to take a decision, at the request of a competent national authority, on whether a research project required authorisation as a ‘clinical trial’ within the meaning of Article 2(2)(2) of Regulation No 536/2014, and that it was in that context that it asked the Commission to clarify whether the continuation of treatment with the medicinal product Mavenclad by repeated administration from year five onwards was covered by the MA.
52 In those circumstances, the contested measure was adopted in order to respond to that request for administrative assistance and not to amend the MA.
53 That assessment is not called into question by the applicant’s argument that, in its letter to the Commission dated 13 January 2025, the BfArM requested the adoption of a legally binding position.
54 In that regard, it should be noted that, in its letter of 13 January 2025, the BfArM informed the Commission that, according to the Verwaltungsgericht Köln (Administrative Court, Cologne, Germany), national regulatory authorities were not authorised to interpret EU acts or to publish information having legal effects vis-à-vis third parties. According to that court, such authorisation may only be granted to the institution which adopted the EU act at issue, in this case the Commission. The BfArM inferred from this that it was required to submit to the Commission the specific question raised in the case in hand, namely whether or not the application at the origin of the research project referred to in paragraph 51 above was covered by the MA.
55 It follows from the content of that letter that the BfArM was seeking to obtain from the Commission, in its capacity as author of the MA, information as to the scope of that MA.
56 That assessment is borne out by the content of the contested measure, which was sent to it by the Commission in response. Indeed, first, the Commission notes that the BfArM’s request seeks confirmation from it concerning the scope of the MA. Second, it merely provides the information requested, reiterating the content of the MA.
57 In the third place, as regards the Commission’s powers concerning the grant, variation and withdrawal of a marketing authorisation and the procedure governing the exercise of those powers, it should be noted that they are provided for in Regulation No 726/2004. According to Article 81(1) of that regulation, all decisions to grant, refuse, vary, suspend, withdraw or revoke a marketing authorisation which are taken in accordance with that regulation are to state in detail the reasons on which they are based. Under Article 81(2) of Regulation No 726/2004, a marketing authorisation may not be granted, refused, varied, suspended, withdrawn or revoked except through the procedures and on the grounds set out in that regulation.
58 As regards, more specifically, the variation of a marketing authorisation, the Commission adopted Regulation (EC) No 1234/2008 of 24 November 2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use (OJ 2008 L 334, p. 7), as amended, Chapter III of which governs variations to centralised marketing authorisations.
59 It follows that the terms of the MA cannot be altered by the contested measure. Indeed, a marketing authorisation granted under Regulation No 726/2004 may be amended or restricted only by means of legal acts adopted following a procedure for variation, in accordance with that regulation and Regulation No 1234/2008. It must be stated that such a procedure was not followed in the present case.
60 Thus, in the contested measure, the Commission did not amend the MA and could not do so without infringing the provisions of Regulations No 726/2004 and No 1234/2008.
61 Furthermore, that finding is borne out by the fact that, as is apparent from paragraph 10 above, and as recalled in paragraph 50 above, the applicant itself submitted, on 22 November 2023, an application for variation of the terms of the MA in order to allow treatment to continue beyond year four, which it subsequently withdrew.
62 As a result, the applicant is not justified in claiming that the contested measure introduces a new restriction on the conditions of use of Mavenclad, thus producing binding legal effects.
63 The contested measure merely provides the information requested as to the scope of the MA in the light of the summary of product characteristics.
64 It follows from the foregoing considerations that the contested measure is not an act producing binding legal effects within the meaning of Article 263 TFEU, with the result that the plea of inadmissibility raised by the Commission must be upheld and, therefore, the action must be dismissed as inadmissible, without it being necessary for the Court to rule on the other arguments raised by the Commission in support of its plea of inadmissibility.
Costs
65 Under Article 134(1) of the Rules of Procedure, the unsuccessful party is to be ordered to pay the costs if they have been applied for in the successful party’s pleadings. As the applicant has been unsuccessful, it must be ordered to pay the costs, including the costs relating to the interim proceedings, in accordance with the form of order sought by the Commission.
On those grounds,
THE GENERAL COURT (Ninth Chamber)
hereby orders:
1. The action is dismissed as inadmissible.
2. Merck Europe BV shall, in addition to bearing its own costs, pay those incurred by the European Commission, including those relating to the proceedings for interim measures.
Luxembourg, 12 October 2026.
T. Henze
S. Kingston
Acting Registrar
President
* Language of the case: English.